[Funding alert] Medtech Company Carthera Secures €4.5 Million Additional Funding

Clinical-stage medical technology startup Carthera is dedicated to creating cutting-edge ultrasound-based medical devices that can be utilised for treating a range of brain conditions. With this funding, Carthera will be enabled to treat recurrent glioblastoma (rGBM) in patients by starting its first registrational trial with its SonoCloud technology.

Read also - Estonia-based Ecobase Raises €2.5M Seed Funding

The company has broadened its investor base by welcoming Unorthodox Ventures, its first US-based venture capital firm. Supernova Invest, Saint-Genys, and Bouscas Med, current shareholders, took part as well.

Frédéric Sottilini, CEO of Carthera shared: “I am pleased to welcome Unorthodox Ventures to our investor base, it is great to see that our program continues to raise interest in the US market. I would also like to thank our historical investors for their continued support, allowing us to fulfil our mission of providing new treatment options to patients with glioblastoma and otheserious brain diseases.

Carey Smith, Founding Contrarian at Unorthodox Ventures, said: “Carthera’s technology addresses a real problem, and we’re pleased to support the company’s work and this pivotal trial.”

About Carthera

Clinical-stage medical technology startup Carthera® has devoted itself to creating cutting-edge ultrasound-based medical devices that are capable of helping treat a variety of severe brain illnesses.

Read also - Metz-based i-Virtual Secures €3 Million in Funding

SonoCloud®, a revolutionary medical technology developed by Carthera®, is a proprietary device that uses ultrasound to temporarily widen blood arteries in the brain.